CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Index level declines can reflect profit-taking, macro shocks, or sector rotations. This intro covers common indicators to read with context.
23,215 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Micron Technology reports record margins and a tight memory market that underscores leverage in the AI era. Apple fac...
U.S. regulators have begun a CIP-based compliance clock for stablecoin issuers, tying direct customer onboarding to f...
Investors confront a tough choice: buy Nvidia for big gains or rely on NVDY's weekly income stream, which comes with ...
Micron Technology has logged an extraordinary 800% rally over the past year, but fresh analysis flags headwinds that ...
Five pivotal reverse mortgage stories from the first half of 2026 reveal how policy debates, consumer protections, an...
A veteran tech analyst challenges the AI-rotation selloff, arguing software names are undervalued as rate fears ease ...
Bitcoin closed June at a two-year low as ETF outflows accelerated and institutional interest remained restrained. The...
As policymakers migrate from restraint to regulation, Washington signals a bipartisan push for federal AI licensing, ...
Snowflake reports a sizable rise in remaining performance obligations, underscoring a strengthening data-backlog thes...
The annual Sun Valley meeting is pivoting from legacy media power to AI and software influence, signaling a new era f...
AMD leads a chip stock rebound with a 7% jump, followed by Intel and Broadcom, as analysts frame the pullback as a bu...